A Phase 4 Study to Evaluate Glucodynamic Effects of Dulaglutide in Japanese Patients With Type 2 Diabetes Mellitus

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCT1080223698

Enrollment

Unknown

Registered

2017-10-31

Start date

2017-10-31

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes Mellitus

Interventions

investigational material(s) Generic name etc : dulaglutide INN of investigational material : Therapeutic category code : 249 Other hormone preparations (including antihormone preparations) Dosage and

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: - Have type 2 diabetes (based on the World Health Organization [WHO] diagnostic criteria) for at least 1 year. - Have diet and exercise therapy only (no oral antihyperglycemic medication for at least 3 months prior to screening). - Have a fasting blood glucose value of =200 milligrams per deciliter (mg/dL) at screening. - Have a screening body weight of =80 kilograms.

Exclusion criteria

Exclusion criteria: - Have known allergies to dulaglutide, or other glucagon-like peptide-1(GLP-1) receptor agonists. - Have had a clinically significant cardiovascular disease. - Have a known clinically significant gastric emptying abnormality or have undergone gastric bypass surgery or restrictive bariatric surgery. - Have acute or chronic hepatitis, signs and symptoms of any other liver disease. - Have a history of chronic pancreatitis or acute idiopathic pancreatitis, or were diagnosed with any type of acute pancreatitis. - Have an estimated glomerular filtration rate (eGFR) <30 milliliters/minute/1.73 meter squared. - In the opinion of the investigator or sponsor, are unsuitable for inclusion in the study.

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026